Developing a System-Wide Protocol for Talquetamab Toxicity Management

EP: 1.Alan's Multiple Myeloma Journey: Facing a New Diagnosis

EP: 2.Connecting With Multiple Myeloma Support Groups and Online Resources

EP: 3.Alan's Treatment Course and Quality-of-Life Goals

EP: 4.Coordinated Health Care Teams and Caregiver Support

EP: 5.Extending Talquetamab Education Beyond the Hospital

EP: 6.Addressing Early Talquetamab Toxicity Concerns

Now Viewing

EP: 7.Developing a System-Wide Protocol for Talquetamab Toxicity Management

EP: 8.Practical Tips for Managing Nail and Skin Changes While Receiving Talquetamab

EP: 9.Managing Taste Changes and Weight Loss During Talquetamab Treatment

EP: 10.Advice for the Patient Starting Treatment With Talquetamab

EP: 11.Advice for the Caregiver: Be a Patient Advocate

EP: 12.Addressing Common Talquetamab Misunderstandings

EP: 13.How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?

Samantha Shenoy, NP, MSN, developed a comprehensive toxicity management protocol based on 5 years of clinical experience with patients on talquetamab, beginning with clinical trial participants. The protocol evolved through consultation with dermatologists, dietitians, colleagues at other institutions, and direct patient feedback about effective management strategies. This collaborative approach resulted in a 3- to 4-page handout covering taste changes, dry mouth, skin changes, nail changes, and weight loss management.

The handout provides practical, actionable recommendations organized by toxicity type, including specific product recommendations for managing each adverse effect category. For skin toxicities, recommendations include using emollients, ammonium lactate cream, and topical steroids for palmar-plantar peeling, along with lukewarm showers and immediate post-shower moisturizing. Nail care strategies involve nail hardeners, vitamin E cuticle oil, protective coverings such as finger cots, and trauma prevention through proper footwear and activity modifications.

The proactive distribution of educational materials before treatment initiation empowers patients to prepare by purchasing recommended products and understanding what to expect during therapy. The protocol emphasizes patient empowerment through preparation, suggesting patients keep materials accessible for ongoing reference rather than attempting to absorb all information at once. This systematic approach to toxicity management represents a scalable model for other institutions implementing bispecific antibody programs.